BIIBBiogen Inc.

BIIB Stock Price, Valuation & Chart | Biogen Inc.

Compare

$222.67+6.63 (+3.07%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Drug Manufacturers - General BIIB intrinsic value BIIB calculated fair value vs price

Overview Financials Dividends Ratios

BIIB Historical price chart

BIIB Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization32.90B

PE Ratio14.06

EPS15.84

Trading Volume1.27M

Today's High/Low225.59/216.97

Dividend Yield0.00

52 Week High/Low225.59/135.39

Shares Outstanding147.75M

BIIB Financial Statement

BIIB Analyst ratings

BIIB Analysis & performance metrics

BIIB Company profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY,…

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL;…

BIIB Management team

Name

Position

Nicole Murphy

Executive Vice President and Head of Pharmaceutical Operations & Technology

Sean Godbout

Chief Accounting Officer & Global Corporate Controller

Tim Power M.B.A., Ph.D.

Head of Investor Relations

Adam Keeney Ph.D.

Executive Vice President & Head of Corporate Development

Robin C. KramerCFO

Executive Vice President & Chief Financial Officer

Priya Singhal M.D., M.P.H.

Executive Vice President & Head of Development

Christopher A. ViehbacherCEO

President, Chief Executive Officer & Director

Susan H. Alexander Esq.

Executive Vice President & Chief Legal Officer

Name

Position

Nicole Murphy

Executive Vice President and Head of Pharmaceutical Operations & Technology

Sean Godbout

Chief Accounting Officer & Global Corporate Controller

Tim Power M.B.A., Ph.D.

Head of Investor Relations

Adam Keeney Ph.D.

Executive Vice President & Head of Corporate Development

Robin C. KramerCFO

Executive Vice President & Chief Financial Officer

Priya Singhal M.D., M.P.H.

Executive Vice President & Head of Development

Christopher A. ViehbacherCEO

President, Chief Executive Officer & Director

Susan H. Alexander Esq.

Executive Vice President & Chief Legal Officer

Management Team

Nicole Murphy

Executive Vice President and Head of Pharmaceutical Operations & Technology

Sean Godbout

Chief Accounting Officer & Global Corporate Controller

Tim Power M.B.A., Ph.D.

Head of Investor Relations

Adam Keeney Ph.D.

Executive Vice President & Head of Corporate Development

Robin C. KramerCFO

Executive Vice President & Chief Financial Officer

Priya Singhal M.D., M.P.H.

Executive Vice President & Head of Development

Christopher A. ViehbacherCEO

President, Chief Executive Officer & Director

Susan H. Alexander Esq.

Executive Vice President & Chief Legal Officer

Management

Nicole Murphy

Executive Vice President and Head of Pharmaceutical Operations & Technology

Sean Godbout

Chief Accounting Officer & Global Corporate Controller

Tim Power M.B.A., Ph.D.

Head of Investor Relations

Adam Keeney Ph.D.

Executive Vice President & Head of Corporate Development

Robin C. KramerCFO

Executive Vice President & Chief Financial Officer

Priya Singhal M.D., M.P.H.

Executive Vice President & Head of Development

Christopher A. ViehbacherCEO

President, Chief Executive Officer & Director

Susan H. Alexander Esq.

Executive Vice President & Chief Legal Officer

Total 8 executives

BIIB Frequently asked questions

What is Biogen Inc. (BIIB) Stock Price?

Current stock price of Biogen Inc. (BIIB) stock is $222.67. The stock price is +3.07% higher in the session. The intraday range can be seen from this page. Volume of Biogen Inc. (BIIB) stock is 1.27M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Biogen Inc. (BIIB) stock price going up or down today?

The stock price of Biogen Inc. (BIIB) can change with earnings, company news, and overall market sentiment. Biogen Inc. operates in the Healthcare / Drug Manufacturers - General market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Biogen Inc. stock expensive at its current price?

Whether Biogen Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for BIIB on this page is 14.06. EPS on this page is 15.84. Compare those figures with peers and growth expectations before deciding if the current Biogen Inc. price is justified.

How has the stock price of Biogen Inc. (BIIB) performed historically?

Historical performance for Biogen Inc. (BIIB) is shown on the price chart on this page. Review multi-period moves alongside volume to see how BIIB reacted to past earnings and market events.

Should I buy Biogen Inc. (BIIB) stock, at this price?

Buying Biogen Inc. (BIIB) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.